Hims & Hers Health reported disappointing Q3 results with subscriber numbers falling quarter-over-quarter and gross margin hitting a new low. The company also gave a weak outlook for Q4 and fiscal year 2026. However, much of this underperformance was intentional as part of a strategy to strengthen the business for 2027 and beyond. Despite current challenges, Hims & Hers trades at a low valuation of 3.5 times 2030 EBITDA, suggesting potential value for long-term investors.
Following Hims & Hers' strategic sacrifices to build future strength, the stock shows notable activity on Pluang. As of Nov 12, 2026 02:41 WIB, HIMS trades at USD 20.64, up 7.89% in one day, with a market cap of $4.48 billion. Despite the recent gains, the stock remains well below its 52-week high of $40.02, reflecting ongoing investor caution. Typical holding time on Pluang is 24 days, with order activity skewed heavily towards selling at 82%.
The global telehealth market, valued at $77.4 billion in 2025, is projected to expand to $187.5 billion by 2033, driven by increasing patient demand for virtual care and advances in AI, remote monitoring, and wearable health devices. Companies like R...
Hims & Hers Health reported Q3 2026 revenue of $890.3 million, slightly missing analyst consensus by $2.5 million but meeting midpoint guidance. The company strategically reduced marketing spend to 28% of revenue, down from 39% the previous year, in ...
Hims & Hers reported a surprise Q3 loss and cut its full-year profit outlook, causing its stock to drop 18%. Despite 48.6% revenue growth, the company missed revenue estimates and faced margin pressure due to lower-margin weight-loss products and int...
Hims & Hers stock dropped 25.67% in a week following its deal with Eli Lilly to expand access to weight-loss drugs, despite Lilly's modest share gains. The decline reflects challenges from Hims' shift to branded GLP-1 drugs, including a drop in gross...
Hims & Hers reported a 49% increase in Q3 revenue to $890.4 million, driven by a 321% surge in international sales, partly due to the acquisition of Eucalyptus. However, gross margins fell sharply from 73.8% to 57.2%, and the company lost 100,000 sub...
